Accurate interpretation of renal allograft biopsy is necessary to guide therapy, especially when an episode biopsy is taken to rescue the graft. Contrarily, a protocol biopsy is carried out routinely to identify baseline conditions (biopsy at 0 or 1 h), subclinical rejection, histological change under current immunosuppression regimen, drug nephrotoxicity, viral infection, and recurrence of glomerulonephritis. Semiquantitative scoring for active lesions including tubulitis, glomerulitis, capillaritis, arteritis, arteriopathy, and others such as polyomavirus infection are key factors in transplant pathology. Recently, the Banff classification has proposed several novel concepts focused on antibody-mediated rejection (ABMR). This review presents the interpretation of transplant pathology from rejection to infection, recurrence of glomerulonephritis, and drug nephrotoxicity, with a description of ABMR according to the 2013 and 2017 Banff classification.
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THE TIME-DEPENDENT PURPOSE OF PROTOCOL BIOPSY
First, 0-or 1-h biopsy immediately after transplant aims to evaluate the baseline state of the donor renal graft. 0-h biopsy is performed to observe baseline graft conditions without blood supply from the recipient; 1-h biopsy helps to observe conditions after recipient blood supply has started, which involves an initial immunological reaction and reperfusion injury. These first-line biopsies are also important to evaluate renal prognosis for recipients as well as donors. Evaluation of histology is based on the Banff classification. 1 In terms of donors, Fahmy et al. showed that interstitial fibrosis and tubular atrophy (IFTA) on 1-h biopsy was predictive of glomerular filtration rate decline in a study of 310 living donors. 2 Generally, IFTA < grade I (<5% of specimen) is considered normal. An approximately 3-month biopsy is done routinely as the first evaluation of initial graft conditions under the current immunosuppression regimen. Within 3 months, clinical or subclinical rejection is often seen. If there is no rejection lesion, current immunosuppression dosage can be reduced. A 1-year biopsy is also performed to check for signs of rejection, calcineurin inhibitor (CNI) nephrotoxicity, BK virus (BKV) nephropathy, chronicity of interstitial inflammation, and recurrence of glomerulonephritis. BKV nephropathy usually occurs within one year after transplantation. In our centre, 1-h protocol biopsy showing glomerular sclerosis could not predict 1-year graft survival, 3 but a recent report showed that 1-year protocol biopsy with histological changes can predict long-term graft survival. 4 Thus, protocol biopsy should be considered for verification of immunosuppression. Subsequently, 3-, 5-, 7-, and even 10-year biopsies can be performed to evaluate for chronic ABMR (CABMR), 1 These biopsy procedures require hospitalization for several days, and it is crucial to detect any malignancy during this time. Death with functioning graft should be avoided by ensuring thorough whole-body examination during this period. General assessment regarding weight control, lipid profile, diabetes, hypertension, and hyperuricaemia are also checked with an emphasis on treatment from an immunological perspective. Consideration of how to reduce immunosuppressant dose, manage non-immunological disorder, and avoid any malignancy/infection is necessary. Malignancy can develop within the late post-transplantation period, 10 and its incidence following transplant is 10 to 20 times higher than in the general population. If malignancy is detected during this hospitalization, immunosuppressant dose should be reduced based on graft function as determined by biopsy findings. 11 Thus, to adequately resect cancer, baseline graft function is critical. On detecting pathological change from protocol biopsy, the possibility of changing diagnosis, changing treatment, and reducing immunosuppression dose is reported to be 36%, 56%, and 22%, respectively. 12 At our institution, Toho University, we presently perform about 200-300 protocol graft biopsies per year.
PROCEDURE OF PROTOCOL BIOPSY
Informed consent for protocol biopsy taken every other year is obtained in advance from all recipients and family members before transplantation. Preparing protocol biopsy involves: (i) ruling out the presence of a clotting abnormality and checking platelet count before hospitalization, and (ii) confirming routine medications in elderly transplant recipients who might be on anticoagulant and antiplatelet agents. If these medications are being used, recipients should be hospitalized earlier after confirming drug holidays. On hospitalization, heparinization is started and stopped just before protocol biopsy. Imaging guidance is also necessary to avoid inadvertent puncture and damage to the iliac artery, vein, ureter, and intestine. Computed tomography (CT) and ultrasonography (US) are routinely used to establish anatomical position and the site of arteriovenous (AV) anastomosis in the graft. In obese recipients, anatomical configuration could change. Also, grafts in obese recipients are often covered by abdominal organs including intestine and colon. Repetitive protocol biopsy leads to formation of AV anastomosis because the biopsy site tends to be at the same puncture point in the lower pole of the graft, especially in obese patients. AV anastomosis was observed in 17.5% of patients after protocol biopsy and occurred within less than 6 months; in over the half of these cases, it disappeared spontaneously. 13 The 16G core-biopsy needle is preferably used, under US guidance. If the biopsy needle cannot puncture the skin easily, a hole is made with an 18G suture needle as a puncture guide. After extracting about two to three specimens, cessation of graft bleeding is ensured by applying manual pressure for 15 min. Full blood count is performed and arteriovenous fistula is assessed with US. Patients stay in bed for 3 h, the bandage is removed the next morning, and the patient is evaluated for worsening of haematoma, macrohaematuria, or anaemia. If the patient has no complications, discharge from hospital can be considered. The histological diagnosis will be relayed to the patients at the next outpatient visit clinic.
Regarding the Banff classification, 1 the nephrologist, transplantation surgeon, and pathologist first evaluate the specimen based on clinical background, and the clinicalpathological conference then determines the strategy for modification of immunosuppressants. For the final check, a pathologist evaluates the pathology report, following which specific staining for SV-40, IgG subclass, and κ/λ light chains and additional electron microscopy are ordered, if necessary. C4d is staining routinely. When obtaining two slices of specimens using a 16G biopsy gun, especially in periodic graft biopsy, one of the slices can often seem like scar tissue and is distinctly different from the other. Such scar tissue-like appearance, which does not indicate the current graft function, may result from Fig. 1 Scar tissue after repetitive protocol biopsy. Two specimens were taken at the same graft biopsy, the top slice seems like scar tissue and is different from the bottom slice. Such scar tissue-like appearance which cannot explain the current graft function, may be because of repetitive needling site infarction.
infarction at the site of repetitive needling (Fig. 1) . Therefore, to ensure diagnostic accuracy, three or more specimens should be taken.
As for the puncture needle size, 16G is preferred to 18G because more specimens can be obtained.
14 Although a report showed increased bleeding in children with the 16G 15 ; for grafts located approximately 1-2 cm below the abdominal wall, it is easier to stop bleeding by manual pressure than for the conventional retroperitoneal own-kidney biopsy.
The recent Banff classification 1 states that electron microscopy evidence of multilayer change in the basement membrane of peritubular capillaries is necessary to confirm a diagnosis of CABMR. For this reason, a sufficient number of specimens are required to evaluate graft function and histology.
RECURRENCE OF GLOMERULONEPHRITIS
Identifying nephritis in a renal graft is another focus of significant interest for nephrologists. Disease onset and progression of nephritis can be observed periodically, contributing to determine the optimal therapy for native kidney disease. For example, recurrent IgA nephropathy, with deposition of new IgA as the initial histological lesion, is often preceded by clinical symptoms like haematuria and proteinuria. 16 In Japan, tonsillectomy is the prevailing standard therapy for native IgA nephropathy. 17 Tonsillectomy could attenuate urinary findings and maintain stability of glomerular lesions in transplant patients. 18, 19 If tonsillectomy is not performed, variables such as mesangial hypercellularity score and glomerular sclerosis index will worsen with disease progression. 20 IgA nephropathy runs a silent course, taking about 10-20 years to reach end-stage renal disease (ESRD), long-term observation is thus necessary to determine the benefits of tonsillectomy based on protocol biopsy findings. High recurrence rate was reported at approximately 30-60% within 3 years after transplantation, with chronic rejection as the main cause of graft loss and not recurrent IgA nephropathy alone. 16 The presence of focal segmental glomerulosclerosis (FSGS) in a specimen should raise suspicion of other disorders based on CNI effect, size mismatch, hypertension, and obesity as differential diagnoses. 21 With recurrence of FSGS, repetitive plasma exchange and rituximab might be effective. 21, 22 Protocol biopsy is useful for confirming treatment outcome in recurrent glomerulonephritis. Clinical symptoms, including massive proteinuria immediately after transplantation, develop alongside the histological features of FSGS. Unlike in IgA nephropathy, FSGS lesions commonly appear later. In cases of FSGS recurrence, the recommendation is to take the biopsy specimen from a site deep within the cortex. Protocol biopsy might reveal evidence of healing such as restored podocyte architecture while light microscopy findings of FSGS remain constant. 22 Diabetes is the most common reason for initiating dialysis in Japan, accounting for about 42% of the entire population of patients starting dialysis. Diabetic recipients also increased to 16% of all kidney transplant recipients in Japan (Japanese Transplant Society website, www.asas.or.jp). Protocol biopsy is also a major tool for detecting the initial lesions of recurrent diabetic nephropathy, showing basement membrane thickening, polar vasculosis and slight mesangial expansion. 23 Within 6 years after transplant, biopsy-proven diabetic nephropathy was observed in recipients with pre-as well as post-transplant DM. 24 Nodule formation is a rare finding because protocol biopsy only shows the initial changes. Biopsy is generally not taken in native diabetic kidney disease, however in diabetes, protocol graft biopsy provides information about the initial histological lesions in diabetes, its progression, and prevention. Blood sugar control is a fundamental strategy for treatment of diabetic nephropathy and the addition of pancreatic transplantation could cause regression of diabetic nodular sclerosis in diabetic patients with kidney transplant alone. This remarkable finding was confirmed by using protocol biopsy.
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TUBULOINTERSTITIAL LESIONS
Although rejection occurs in the cortex, it is possible to diagnose rejection based on the presence of medullary cellular infiltration or tubulitis. 27 However, cellular infiltration involving a 1-2-mm width of the subcapsular area reflects prior endoscopic surgery with manual removal of kidney and is of no pathological significance (Fig. 2) . This subcapsular cellular infiltration may increase in incidence due to the widespread application of endoscopic surgeries in recent years. The finding of continuous spread of pathological change extending from the subcapsular to the cortical region is significant for rejection. Fundamental diagnosis of acute T-cell mediated rejection (TCMR) requires 25% of infiltration (i2-i3) in the overall area of the specimen. Also, TCMR grade IA or IB is determined by extent of tubulitis (t2-t3) with i2-i3 lesions. 1 It is important not to consider interstitial cell infiltration around fibrotic areas as evidence of TCMR (Fig. 3) . The 2017 Banff classification proposed that the inflammatory cellular infiltration on IFTA area 28 (iIFTA) had a similar proinflammatory transcription profile but worse prognosis than IFTA alone. This is partly due to 'underimmunosuppression' and post TCMR outcome. 29 This suggests that the extent of inflammatory cell infiltration in IFTA from protocol biopsy should be interpreted with caution. For borderline changes, it has been discussed as to whether tubulointerstitial inflammation, which does not meet the criteria for TCMR, should be treated or not. Furthermore, Rush et al. 30 and we 31 reported in the 1990s, treatment of borderline changes with bolus steroid therapy led to favourable outcomes. It is important to note that TCMR with humoural components may produce DSAs in the graft resulting in poor outcome. 32 Inflammation alone without definitive rejection and IFTA is strongly associated with 15-year graft survival. 33 The question now is what is the role of these inflammatory cells in kidney allograft other than rejection. Wohlfahrtove et al. showed that the transcriptional profile (chemokines and TGF-β expression using real-time polymerase chain reaction assay) of subclinical inflammatory cells is indicative of immune glomerular injury, but to a lower extent compared with the profile in clinical acute rejection. 34 Next, to distinguish rejection from tubulitis, it must be noted that rejection may occur starting from the distal and extending to the proximal tubules. Also, infection of the distal collecting tubules, such as BKV infection, can mimic rejection (Fig. 4) . This can be ruled out by combining evidence from immunostaining for simian virus 40 35 and blood/urine BKV identification by PCR. BKV nephropathy does not typically involve arteritis, which is an important distinguishing feature from TCMR. 36 Furthermore, the treatment strategy is totally different, one requires increasing the immunosuppressant dose, the other does not but essentially requires reduction of immunosuppressant dose for treatment of BKV nephropathy. Protocol biopsy is also important for follow-up in the management of BKV nephropathy after reducing the dose of immunosuppressants.
VASCULAR LESIONS
The 2013 Banff classification 1 states that the diagnosis of ABMR requires the characteristic pathological finding of concomitant DSA. Other pathologic findings have also been described. Thrombotic microangiopathy and acute tubular necrosis (both regarded as secondary clinical variations) accompany vasculitis, which includes glomerular capillaritis, peritubular capillaritis (PTCitis), and arteritis. C4d positivity was considered less important in the 2013 Banff classification, whereas endothelial activation seen in glomerulitis and PTCitis (g + PTC; so-called microvascular inflammation) on light microscopy became more important. Early determination of microvascular inflammation sum score (g + PTC > 2) is predictive of ABMR progression. 1 However, in the more recent 2017 Banff classification, C4d scoring has been reappraised. C4d linear positive staining without DSA is still diagnostic for active ABMR with histological evidence. 28 Non-detectable DSA or non-HLA-related antibodies are still considered the underlying pathology of ABMR. Figure 5 (a,b) shows [g + PTC] seen on 1-h biopsy specimen in hyperacute rejection. The microvascular inflammation seen on early protocol biopsy suggests that DSA can appear later. At our institution, we usually perform anti-HLA antibody serology when microvascular inflammation (g + PTC > 2) is seen on protocol biopsy.
GLOMERULAR LESIONS
The finding of glomerular double contours (cg) in the capillary wall is designated as CABMR. There is also significant correlation between cg and DSA positivity. If only a part of the glomerular capillary shows cg, a definitive diagnosis of cg can be made. 1 Cg results from repeated vascular endothelium attacks, causing widening of the subendothelial space and new formation of basement membrane (Fig. 6) . In latephase protocol biopsy or in recipients with medication nonadherence, a mesangiocapillary glomerulitis pattern is often seen. Under these conditions, with C4d deposition in the glomerular capillary wall, a diagnosis of transplant glomerulopathy can be made, which is a phenotype of CABMR. This often presents as nephrotic syndrome and is refractory to treatment.
CNI NEPHROTOXICITY
Following the introduction of CNI in 1990, the incidence of acute rejection decreased and graft survival improved for (Fig. 6a) results from repeated vascular-endothelium attacks causing widening of the subendothelial space and new formation of basement membrane (Fig. 6b) . C4d deposition in the glomerular capillary wall allows for diagnosis of transplant glomerulopathy.
the short-to mid-term following kidney transplantation. However, long-term graft survival did not change partly due to chronic CNI nephrotoxicity. In terms of CNI arteriolopathy, 100% prevalence in 10-year graft biopsy after transplantation was reported. 8 Conversely, in other fields of organ transplant aside from the kidney, it was reported that 7-23% of cases progressed to ESRD caused by CNI nephrotoxicity within 5 years after organ transplantation. 37 Chronic CNI nephrotoxicity can be effectively evaluated with parameters such as FSGS, striped interstitial fibrosis, tubular atrophy, and arteriolar hyalinosis (ah) on pathological examination. All of the above pathological changes also show non-specific progression in ageing, diabetes, and hypertension. For evaluation of CNI-arteriolopathy, hyaline arteriolar thickening (ahh) was proposed instead of ah, which was earlier proposed in the 2007 Banff classification. At our centre, the incidence of CNI arteriopathy reduced more in 10-year graft biopsy compared with data reported by Nankivell et al. 8 We found a 50-60% prevalence with a minimum dose of CNI (in press). Indeed, long-term exposure is responsible for CNI vasculopathy, and it is important to reduce CNI dose and switch from CNI to another agent like everolimus. Acute rejection increases the required dose of CNI, therefore preventing acute rejection is a basic strategy for preventing CNI nephrotoxicity.
CONCLUSION
We reviewed the relevance of protocol biopsy focusing on rejection, infection, recurrence of glomerulonephritis, and CNI toxicity, which affect long-term graft outcomes. Early determination of microvascular inflammation sum score (g + PTC > 2) is becoming increasingly important to treat these conditions and avoid complete ABMR. Furthermore, regarding iIFTA also, protocol biopsy is important for surveillance and treatment of rejection. Although an alternative analytical method other than pathological diagnosis called an endothelial associated transcript (ENDAT) is gaining prominence, pathological examination is still important as it is cheap and readily available. Protocol biopsy in particular is useful to identify lesions, predict the risk of graft failure, and guide future directions for both recipients and donors.
